Clinical Trial: NCT06139406
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2026-09-25 |
Study Overview
Brief Summary
The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) [Part A: Dose Escalation] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs [Part B: Dose Expansion].
Official Title
A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Conditions
Lymphoma, Non-Hodgkin
Intervention / Treatment
- Drug: JNJ-87801493
- Drug: JNJ-80948543
- Drug: JNJ-75348780
Other Study ID Numbers
- 87801493LYM1001
- 87801493LYM1001
- 2023-505165-93-00
- 2023
Start Date (Actual)
2023-12-06
Primary Completion Date (Actual)
2026-01-30
Study Completion Date (Estimated)
2026-09-30
Enrollment (Actual)
70
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2026-09-25 |
Study Overview
Brief Summary
The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) [Part A: Dose Escalation] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs [Part B: Dose Expansion].
Official Title
A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Conditions
Lymphoma, Non-Hodgkin
Intervention / Treatment
- Drug: JNJ-87801493
- Drug: JNJ-80948543
- Drug: JNJ-75348780
Other Study ID Numbers
- 87801493LYM1001
- 87801493LYM1001
- 2023-505165-93-00
- 2023
Start Date (Actual)
2023-12-06
Primary Completion Date (Actual)
2026-01-30
Study Completion Date (Estimated)
2026-09-30
Enrollment (Actual)
70
Study Type
Interventional
Phase
Phase 1